http://142-54-23-223.fusionmedialtd.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 15 Jul 2026 07:48:02 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://142-54-23-223.fusionmedialtd.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Analyst+Comments/Capricor+Therapeutics+%28CAPR%29+Reiterated+at+Overweight+by+Cantor+Fitzgerald+/26770977.html <p>Cantor Fitzgerald analyst Kristen Kluska reiterated an Overweight rating and $62.00 price target on Capricor Therapeutics (NASDAQ: CAPR).</p><p>The analyst commented, "Why meet? This could serve as one of the first Fireside Chats and chances to meet with management after the PDUFA for deramiocel (cardiosphere-derived cell therapy) for DMD (severe muscle weakness and wasting condition) on August 22nd. Investors can digest the FDA decision at length with the company, as well as hear what the latest is related to the litigation with NS Pharma (NC). Where we'll differentiate: Our expectation at this time is an approval, and we will be able http://www.streetinsider.com/Analyst+Comments/Capricor+Therapeutics+%28CAPR%29+Reiterated+at+Overweight+by+Cantor+Fitzgerald+/26770977.html Wed, 15 Jul 2026 07:48:02 -0400 CAPR http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++CAPRICOR+THERAPEUTICS%2C++++For%3A+Jul+09/26768985.html si-local-file:///var/storage/secattach/20260714/26768985.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++CAPRICOR+THERAPEUTICS%2C++++For%3A+Jul+09/26768985.html Tue, 14 Jul 2026 17:06:00 -0400 CAPR O.03796190 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++CAPRICOR+THERAPEUTICS%2C++++For%3A+Jul+09/26768985.html si-local-file:///var/storage/secattach/20260714/26768985.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++CAPRICOR+THERAPEUTICS%2C++++For%3A+Jul+09/26768985.html Tue, 14 Jul 2026 17:06:00 -0400 CAPR O.03796190 http://www.streetinsider.com/Analyst+Comments/Capricor+Therapeutics+%28CAPR%29+Reiterates+Overweight+Rating+Ahead+of+Upcoming+PDUFA+/26738299.html <p>Cantor Fitzgerald analyst Kristen Kluska reiterated an Overweight rating and $62.00 price target on Capricor Therapeutics (NASDAQ: CAPR).</p><p>The analyst commented, "CAPR has an upcoming regulatory catalyst: PDUFA for deramiocel (CAP-1002; cardiosphere-derived cell therapy) in DMD on 8/22/26. The upcoming PDUFA has become an even greater focus for investors following the recent scheduling of an AdCom on 7/29/26 and the ongoing litigation with NS Pharma (NC). Against this backdrop, we are publishing our latest thoughts on the stock and why we believe deramiocel's data package is compelling and well positioned to support approval. We'd be buyers of the stock right now, http://www.streetinsider.com/Analyst+Comments/Capricor+Therapeutics+%28CAPR%29+Reiterates+Overweight+Rating+Ahead+of+Upcoming+PDUFA+/26738299.html Tue, 07 Jul 2026 07:18:44 -0400 CAPR http://www.streetinsider.com/SEC+Filings/Form++4++++++++++CAPRICOR+THERAPEUTICS%2C++++For%3A+Jun+25++Filed+by%3A+Bergmann+Anthony/26708137.html si-local-file:///var/storage/secattach/20260629/26708137.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++CAPRICOR+THERAPEUTICS%2C++++For%3A+Jun+25++Filed+by%3A+Bergmann+Anthony/26708137.html Mon, 29 Jun 2026 21:30:00 -0400 CAPR O.03796190 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++CAPRICOR+THERAPEUTICS%2C++++For%3A+Jun+25++Filed+by%3A+Bergmann+Anthony/26708137.html si-local-file:///var/storage/secattach/20260629/26708137.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++CAPRICOR+THERAPEUTICS%2C++++For%3A+Jun+25++Filed+by%3A+Bergmann+Anthony/26708137.html Mon, 29 Jun 2026 21:30:00 -0400 CAPR O.03796190 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++CAPRICOR+THERAPEUTICS%2C++++For%3A+Jun+25++Filed+by%3A+Krasney+Karen/26708138.html si-local-file:///var/storage/secattach/20260629/26708138.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++CAPRICOR+THERAPEUTICS%2C++++For%3A+Jun+25++Filed+by%3A+Krasney+Karen/26708138.html Mon, 29 Jun 2026 21:30:00 -0400 CAPR O.03796190 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++CAPRICOR+THERAPEUTICS%2C++++For%3A+Jun+25++Filed+by%3A+Krasney+Karen/26708138.html si-local-file:///var/storage/secattach/20260629/26708138.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++CAPRICOR+THERAPEUTICS%2C++++For%3A+Jun+25++Filed+by%3A+Krasney+Karen/26708138.html Mon, 29 Jun 2026 21:30:00 -0400 CAPR O.03796190 http://www.streetinsider.com/Options/Capricor+Therapeutics+%28CAPR%29+4500+contracts+of+August+30+calls+and+2900+contracts+of+August+20+puts+trade/26701188.html <p>Capricor Therapeutics (NASDAQ: CAPR) 30-day option implied volatility is at 131; compared to its 52-week range of 66 to 422. Call put ratio 1 1call to 1 put with a focus on 4500 contracts of August 30 calls and 2900 contracts of August 20 puts.</p> http://www.streetinsider.com/Options/Capricor+Therapeutics+%28CAPR%29+4500+contracts+of+August+30+calls+and+2900+contracts+of+August+20+puts+trade/26701188.html Mon, 29 Jun 2026 05:58:53 -0400 CAPR http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++CAPRICOR+THERAPEUTICS%2C++++For%3A+Jun+26/26699912.html si-local-file:///var/storage/secattach/20260626/26699912.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++CAPRICOR+THERAPEUTICS%2C++++For%3A+Jun+26/26699912.html Fri, 26 Jun 2026 17:15:00 -0400 CAPR O.03796190 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++CAPRICOR+THERAPEUTICS%2C++++For%3A+Jun+26/26699912.html si-local-file:///var/storage/secattach/20260626/26699912.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++CAPRICOR+THERAPEUTICS%2C++++For%3A+Jun+26/26699912.html Fri, 26 Jun 2026 17:15:00 -0400 CAPR O.03796190 http://www.streetinsider.com/FDA/FDA+to+review+Capricor%27s+DMD+therapy+at+July+advisory+meeting/26695914.html <p>Capricor Therapeutics (NASDAQ: CAPR) announced that the FDA's Cellular, Tissue, and Gene Therapies Advisory Committee (CTGTAC) is scheduled to meet July 29, 2026, to discuss the company's Biologics License Application (BLA) for deramiocel, an investigational cell therapy for Duchenne muscular dystrophy (DMD).</p> <p>The BLA carries a Prescription Drug User Fee Act (PDUFA) target action date of August 22, 2026. The advisory committee meeting will be available for live streaming.</p> <p>The BLA is supported by data from the Phase 2 HOPE-2 trial, long-term outcomes from the HOPE-2-OLE trial, and results from the Phase 3 HOPE-3 trial. According to the company, HOPE-3 achieved statistical http://www.streetinsider.com/FDA/FDA+to+review+Capricor%27s+DMD+therapy+at+July+advisory+meeting/26695914.html Fri, 26 Jun 2026 10:02:52 -0400 A.06822034 A.25015717 A.31066700 CAPR O.03796190 O.09788428 O.20026344 O.22422661 http://www.streetinsider.com/FDA/FDA+to+review+Capricor%27s+DMD+therapy+at+July+advisory+meeting/26695914.html <p>Capricor Therapeutics (NASDAQ: CAPR) announced that the FDA's Cellular, Tissue, and Gene Therapies Advisory Committee (CTGTAC) is scheduled to meet July 29, 2026, to discuss the company's Biologics License Application (BLA) for deramiocel, an investigational cell therapy for Duchenne muscular dystrophy (DMD).</p> <p>The BLA carries a Prescription Drug User Fee Act (PDUFA) target action date of August 22, 2026. The advisory committee meeting will be available for live streaming.</p> <p>The BLA is supported by data from the Phase 2 HOPE-2 trial, long-term outcomes from the HOPE-2-OLE trial, and results from the Phase 3 HOPE-3 trial. According to the company, HOPE-3 achieved statistical http://www.streetinsider.com/FDA/FDA+to+review+Capricor%27s+DMD+therapy+at+July+advisory+meeting/26695914.html Fri, 26 Jun 2026 10:02:52 -0400 A.06822034 A.25015717 A.31066700 CAPR O.03796190 O.09788428 O.20026344 O.22422661 http://www.streetinsider.com/FDA/FDA+to+review+Capricor%27s+DMD+therapy+at+July+advisory+meeting/26695914.html <p>Capricor Therapeutics (NASDAQ: CAPR) announced that the FDA's Cellular, Tissue, and Gene Therapies Advisory Committee (CTGTAC) is scheduled to meet July 29, 2026, to discuss the company's Biologics License Application (BLA) for deramiocel, an investigational cell therapy for Duchenne muscular dystrophy (DMD).</p> <p>The BLA carries a Prescription Drug User Fee Act (PDUFA) target action date of August 22, 2026. The advisory committee meeting will be available for live streaming.</p> <p>The BLA is supported by data from the Phase 2 HOPE-2 trial, long-term outcomes from the HOPE-2-OLE trial, and results from the Phase 3 HOPE-3 trial. According to the company, HOPE-3 achieved statistical http://www.streetinsider.com/FDA/FDA+to+review+Capricor%27s+DMD+therapy+at+July+advisory+meeting/26695914.html Fri, 26 Jun 2026 10:02:52 -0400 A.06822034 A.25015717 A.31066700 CAPR O.03796190 O.09788428 O.20026344 O.22422661 http://www.streetinsider.com/FDA/FDA+to+review+Capricor%27s+DMD+therapy+at+July+advisory+meeting/26695914.html <p>Capricor Therapeutics (NASDAQ: CAPR) announced that the FDA's Cellular, Tissue, and Gene Therapies Advisory Committee (CTGTAC) is scheduled to meet July 29, 2026, to discuss the company's Biologics License Application (BLA) for deramiocel, an investigational cell therapy for Duchenne muscular dystrophy (DMD).</p> <p>The BLA carries a Prescription Drug User Fee Act (PDUFA) target action date of August 22, 2026. The advisory committee meeting will be available for live streaming.</p> <p>The BLA is supported by data from the Phase 2 HOPE-2 trial, long-term outcomes from the HOPE-2-OLE trial, and results from the Phase 3 HOPE-3 trial. According to the company, HOPE-3 achieved statistical http://www.streetinsider.com/FDA/FDA+to+review+Capricor%27s+DMD+therapy+at+July+advisory+meeting/26695914.html Fri, 26 Jun 2026 10:02:52 -0400 A.06822034 A.25015717 A.31066700 CAPR O.03796190 O.09788428 O.20026344 O.22422661 http://www.streetinsider.com/FDA/FDA+to+review+Capricor%27s+DMD+therapy+at+July+advisory+meeting/26695914.html <p>Capricor Therapeutics (NASDAQ: CAPR) announced that the FDA's Cellular, Tissue, and Gene Therapies Advisory Committee (CTGTAC) is scheduled to meet July 29, 2026, to discuss the company's Biologics License Application (BLA) for deramiocel, an investigational cell therapy for Duchenne muscular dystrophy (DMD).</p> <p>The BLA carries a Prescription Drug User Fee Act (PDUFA) target action date of August 22, 2026. The advisory committee meeting will be available for live streaming.</p> <p>The BLA is supported by data from the Phase 2 HOPE-2 trial, long-term outcomes from the HOPE-2-OLE trial, and results from the Phase 3 HOPE-3 trial. According to the company, HOPE-3 achieved statistical http://www.streetinsider.com/FDA/FDA+to+review+Capricor%27s+DMD+therapy+at+July+advisory+meeting/26695914.html Fri, 26 Jun 2026 10:02:52 -0400 A.06822034 A.25015717 A.31066700 CAPR O.03796190 O.09788428 O.20026344 O.22422661 http://www.streetinsider.com/FDA/FDA+to+review+Capricor%27s+DMD+therapy+at+July+advisory+meeting/26695914.html <p>Capricor Therapeutics (NASDAQ: CAPR) announced that the FDA's Cellular, Tissue, and Gene Therapies Advisory Committee (CTGTAC) is scheduled to meet July 29, 2026, to discuss the company's Biologics License Application (BLA) for deramiocel, an investigational cell therapy for Duchenne muscular dystrophy (DMD).</p> <p>The BLA carries a Prescription Drug User Fee Act (PDUFA) target action date of August 22, 2026. The advisory committee meeting will be available for live streaming.</p> <p>The BLA is supported by data from the Phase 2 HOPE-2 trial, long-term outcomes from the HOPE-2-OLE trial, and results from the Phase 3 HOPE-3 trial. According to the company, HOPE-3 achieved statistical http://www.streetinsider.com/FDA/FDA+to+review+Capricor%27s+DMD+therapy+at+July+advisory+meeting/26695914.html Fri, 26 Jun 2026 10:02:52 -0400 A.06822034 A.25015717 A.31066700 CAPR O.03796190 O.09788428 O.20026344 O.22422661 http://www.streetinsider.com/FDA/FDA+to+review+Capricor%27s+DMD+therapy+at+July+advisory+meeting/26695914.html <p>Capricor Therapeutics (NASDAQ: CAPR) announced that the FDA's Cellular, Tissue, and Gene Therapies Advisory Committee (CTGTAC) is scheduled to meet July 29, 2026, to discuss the company's Biologics License Application (BLA) for deramiocel, an investigational cell therapy for Duchenne muscular dystrophy (DMD).</p> <p>The BLA carries a Prescription Drug User Fee Act (PDUFA) target action date of August 22, 2026. The advisory committee meeting will be available for live streaming.</p> <p>The BLA is supported by data from the Phase 2 HOPE-2 trial, long-term outcomes from the HOPE-2-OLE trial, and results from the Phase 3 HOPE-3 trial. According to the company, HOPE-3 achieved statistical http://www.streetinsider.com/FDA/FDA+to+review+Capricor%27s+DMD+therapy+at+July+advisory+meeting/26695914.html Fri, 26 Jun 2026 10:02:52 -0400 A.06822034 A.25015717 A.31066700 CAPR O.03796190 O.09788428 O.20026344 O.22422661 http://www.streetinsider.com/FDA/FDA+to+review+Capricor%27s+DMD+therapy+at+July+advisory+meeting/26695914.html <p>Capricor Therapeutics (NASDAQ: CAPR) announced that the FDA's Cellular, Tissue, and Gene Therapies Advisory Committee (CTGTAC) is scheduled to meet July 29, 2026, to discuss the company's Biologics License Application (BLA) for deramiocel, an investigational cell therapy for Duchenne muscular dystrophy (DMD).</p> <p>The BLA carries a Prescription Drug User Fee Act (PDUFA) target action date of August 22, 2026. The advisory committee meeting will be available for live streaming.</p> <p>The BLA is supported by data from the Phase 2 HOPE-2 trial, long-term outcomes from the HOPE-2-OLE trial, and results from the Phase 3 HOPE-3 trial. According to the company, HOPE-3 achieved statistical http://www.streetinsider.com/FDA/FDA+to+review+Capricor%27s+DMD+therapy+at+July+advisory+meeting/26695914.html Fri, 26 Jun 2026 10:02:52 -0400 A.06822034 A.25015717 A.31066700 CAPR O.03796190 O.09788428 O.20026344 O.22422661 http://www.streetinsider.com/Press+Releases/Capricor+Therapeutics+Announces+FDA+Advisory+Committee+Meeting+to+Review+BLA+for+Deramiocel+for+the+Treatment+of+Duchenne+Muscular+Dystrophy/26695910.html <p align="center"><em>–Advisory Committee meeting scheduled for July 29, 2026–</em><br/><em>–Company&apos;s Biologics License Application on track with PDUFA target action date of August 22, 2026–</em></p> <p align="justify">SAN DIEGO, June 26, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=AZcayUcDGZHovCSDoZdE7qPvZOqELzOSExPNopIqX1qKQQKSEWJRQ4LLvXP6FsP1omF3c_iOv4TkY_Iif9If9xqEfRhfp7sL19uZ2dNdLmdJAow914iFJTObmSM2ROKqXwgSbkmsZptlnShlYy8KWryZWI7hUzHPR4g5hj_x1vTdQLCyyczizUgf09B5kLmANdi8dutE9USComoAVelaQlLdJ304Gznwpab0wDkuj27J1BPmTshgs5AojjZEnOzoyDZbT8JzY_YiQgTlBqYO5oDfUoQzChMFa5M20N-AzGfZxXo2Uq28iMS8cw0lat82RZ0qjD72Px58vdVEm_qAmrB9XbiaK4V6miEUQZ78QvhiVQP4zW-CZxm4n8MsX7KGYV5LWOaQWan0BP1RmhAl_9XTBY94HN34cpcV2YVrIiVG3KnVsHPifyjBrwCLjUKE" rel="nofollow" target="_blank">Capricor Therapeutics</a> (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today announced that the Cellular, Tissue, and Gene Therapies Advisory Committee (CTGTAC) of the U.S. Food and Drug Administration (FDA) is planning to convene an advisory committee meeting to discuss the Company&apos;s Biologics License Application (BLA) seeking approval of Deramiocel, an investigational cell therapy for http://www.streetinsider.com/Press+Releases/Capricor+Therapeutics+Announces+FDA+Advisory+Committee+Meeting+to+Review+BLA+for+Deramiocel+for+the+Treatment+of+Duchenne+Muscular+Dystrophy/26695910.html Fri, 26 Jun 2026 10:02:00 -0400 A.06822034 A.25015717 A.31066700 CAPR O.03796190 O.09788428 O.20026344 O.22422661 http://www.streetinsider.com/Press+Releases/Capricor+Therapeutics+Announces+FDA+Advisory+Committee+Meeting+to+Review+BLA+for+Deramiocel+for+the+Treatment+of+Duchenne+Muscular+Dystrophy/26695910.html <p align="center"><em>–Advisory Committee meeting scheduled for July 29, 2026–</em><br/><em>–Company&apos;s Biologics License Application on track with PDUFA target action date of August 22, 2026–</em></p> <p align="justify">SAN DIEGO, June 26, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=AZcayUcDGZHovCSDoZdE7qPvZOqELzOSExPNopIqX1qKQQKSEWJRQ4LLvXP6FsP1omF3c_iOv4TkY_Iif9If9xqEfRhfp7sL19uZ2dNdLmdJAow914iFJTObmSM2ROKqXwgSbkmsZptlnShlYy8KWryZWI7hUzHPR4g5hj_x1vTdQLCyyczizUgf09B5kLmANdi8dutE9USComoAVelaQlLdJ304Gznwpab0wDkuj27J1BPmTshgs5AojjZEnOzoyDZbT8JzY_YiQgTlBqYO5oDfUoQzChMFa5M20N-AzGfZxXo2Uq28iMS8cw0lat82RZ0qjD72Px58vdVEm_qAmrB9XbiaK4V6miEUQZ78QvhiVQP4zW-CZxm4n8MsX7KGYV5LWOaQWan0BP1RmhAl_9XTBY94HN34cpcV2YVrIiVG3KnVsHPifyjBrwCLjUKE" rel="nofollow" target="_blank">Capricor Therapeutics</a> (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today announced that the Cellular, Tissue, and Gene Therapies Advisory Committee (CTGTAC) of the U.S. Food and Drug Administration (FDA) is planning to convene an advisory committee meeting to discuss the Company&apos;s Biologics License Application (BLA) seeking approval of Deramiocel, an investigational cell therapy for http://www.streetinsider.com/Press+Releases/Capricor+Therapeutics+Announces+FDA+Advisory+Committee+Meeting+to+Review+BLA+for+Deramiocel+for+the+Treatment+of+Duchenne+Muscular+Dystrophy/26695910.html Fri, 26 Jun 2026 10:02:00 -0400 A.06822034 A.25015717 A.31066700 CAPR O.03796190 O.09788428 O.20026344 O.22422661 http://www.streetinsider.com/Press+Releases/Capricor+Therapeutics+Announces+FDA+Advisory+Committee+Meeting+to+Review+BLA+for+Deramiocel+for+the+Treatment+of+Duchenne+Muscular+Dystrophy/26695910.html <p align="center"><em>–Advisory Committee meeting scheduled for July 29, 2026–</em><br/><em>–Company&apos;s Biologics License Application on track with PDUFA target action date of August 22, 2026–</em></p> <p align="justify">SAN DIEGO, June 26, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=AZcayUcDGZHovCSDoZdE7qPvZOqELzOSExPNopIqX1qKQQKSEWJRQ4LLvXP6FsP1omF3c_iOv4TkY_Iif9If9xqEfRhfp7sL19uZ2dNdLmdJAow914iFJTObmSM2ROKqXwgSbkmsZptlnShlYy8KWryZWI7hUzHPR4g5hj_x1vTdQLCyyczizUgf09B5kLmANdi8dutE9USComoAVelaQlLdJ304Gznwpab0wDkuj27J1BPmTshgs5AojjZEnOzoyDZbT8JzY_YiQgTlBqYO5oDfUoQzChMFa5M20N-AzGfZxXo2Uq28iMS8cw0lat82RZ0qjD72Px58vdVEm_qAmrB9XbiaK4V6miEUQZ78QvhiVQP4zW-CZxm4n8MsX7KGYV5LWOaQWan0BP1RmhAl_9XTBY94HN34cpcV2YVrIiVG3KnVsHPifyjBrwCLjUKE" rel="nofollow" target="_blank">Capricor Therapeutics</a> (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today announced that the Cellular, Tissue, and Gene Therapies Advisory Committee (CTGTAC) of the U.S. Food and Drug Administration (FDA) is planning to convene an advisory committee meeting to discuss the Company&apos;s Biologics License Application (BLA) seeking approval of Deramiocel, an investigational cell therapy for http://www.streetinsider.com/Press+Releases/Capricor+Therapeutics+Announces+FDA+Advisory+Committee+Meeting+to+Review+BLA+for+Deramiocel+for+the+Treatment+of+Duchenne+Muscular+Dystrophy/26695910.html Fri, 26 Jun 2026 10:02:00 -0400 A.06822034 A.25015717 A.31066700 CAPR O.03796190 O.09788428 O.20026344 O.22422661 http://www.streetinsider.com/Press+Releases/Capricor+Therapeutics+Announces+FDA+Advisory+Committee+Meeting+to+Review+BLA+for+Deramiocel+for+the+Treatment+of+Duchenne+Muscular+Dystrophy/26695910.html <p align="center"><em>–Advisory Committee meeting scheduled for July 29, 2026–</em><br/><em>–Company&apos;s Biologics License Application on track with PDUFA target action date of August 22, 2026–</em></p> <p align="justify">SAN DIEGO, June 26, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=AZcayUcDGZHovCSDoZdE7qPvZOqELzOSExPNopIqX1qKQQKSEWJRQ4LLvXP6FsP1omF3c_iOv4TkY_Iif9If9xqEfRhfp7sL19uZ2dNdLmdJAow914iFJTObmSM2ROKqXwgSbkmsZptlnShlYy8KWryZWI7hUzHPR4g5hj_x1vTdQLCyyczizUgf09B5kLmANdi8dutE9USComoAVelaQlLdJ304Gznwpab0wDkuj27J1BPmTshgs5AojjZEnOzoyDZbT8JzY_YiQgTlBqYO5oDfUoQzChMFa5M20N-AzGfZxXo2Uq28iMS8cw0lat82RZ0qjD72Px58vdVEm_qAmrB9XbiaK4V6miEUQZ78QvhiVQP4zW-CZxm4n8MsX7KGYV5LWOaQWan0BP1RmhAl_9XTBY94HN34cpcV2YVrIiVG3KnVsHPifyjBrwCLjUKE" rel="nofollow" target="_blank">Capricor Therapeutics</a> (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today announced that the Cellular, Tissue, and Gene Therapies Advisory Committee (CTGTAC) of the U.S. Food and Drug Administration (FDA) is planning to convene an advisory committee meeting to discuss the Company&apos;s Biologics License Application (BLA) seeking approval of Deramiocel, an investigational cell therapy for http://www.streetinsider.com/Press+Releases/Capricor+Therapeutics+Announces+FDA+Advisory+Committee+Meeting+to+Review+BLA+for+Deramiocel+for+the+Treatment+of+Duchenne+Muscular+Dystrophy/26695910.html Fri, 26 Jun 2026 10:02:00 -0400 A.06822034 A.25015717 A.31066700 CAPR O.03796190 O.09788428 O.20026344 O.22422661 http://www.streetinsider.com/Press+Releases/Capricor+Therapeutics+Announces+FDA+Advisory+Committee+Meeting+to+Review+BLA+for+Deramiocel+for+the+Treatment+of+Duchenne+Muscular+Dystrophy/26695910.html <p align="center"><em>–Advisory Committee meeting scheduled for July 29, 2026–</em><br/><em>–Company&apos;s Biologics License Application on track with PDUFA target action date of August 22, 2026–</em></p> <p align="justify">SAN DIEGO, June 26, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=AZcayUcDGZHovCSDoZdE7qPvZOqELzOSExPNopIqX1qKQQKSEWJRQ4LLvXP6FsP1omF3c_iOv4TkY_Iif9If9xqEfRhfp7sL19uZ2dNdLmdJAow914iFJTObmSM2ROKqXwgSbkmsZptlnShlYy8KWryZWI7hUzHPR4g5hj_x1vTdQLCyyczizUgf09B5kLmANdi8dutE9USComoAVelaQlLdJ304Gznwpab0wDkuj27J1BPmTshgs5AojjZEnOzoyDZbT8JzY_YiQgTlBqYO5oDfUoQzChMFa5M20N-AzGfZxXo2Uq28iMS8cw0lat82RZ0qjD72Px58vdVEm_qAmrB9XbiaK4V6miEUQZ78QvhiVQP4zW-CZxm4n8MsX7KGYV5LWOaQWan0BP1RmhAl_9XTBY94HN34cpcV2YVrIiVG3KnVsHPifyjBrwCLjUKE" rel="nofollow" target="_blank">Capricor Therapeutics</a> (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today announced that the Cellular, Tissue, and Gene Therapies Advisory Committee (CTGTAC) of the U.S. Food and Drug Administration (FDA) is planning to convene an advisory committee meeting to discuss the Company&apos;s Biologics License Application (BLA) seeking approval of Deramiocel, an investigational cell therapy for http://www.streetinsider.com/Press+Releases/Capricor+Therapeutics+Announces+FDA+Advisory+Committee+Meeting+to+Review+BLA+for+Deramiocel+for+the+Treatment+of+Duchenne+Muscular+Dystrophy/26695910.html Fri, 26 Jun 2026 10:02:00 -0400 A.06822034 A.25015717 A.31066700 CAPR O.03796190 O.09788428 O.20026344 O.22422661 http://www.streetinsider.com/Press+Releases/Capricor+Therapeutics+Announces+FDA+Advisory+Committee+Meeting+to+Review+BLA+for+Deramiocel+for+the+Treatment+of+Duchenne+Muscular+Dystrophy/26695910.html <p align="center"><em>–Advisory Committee meeting scheduled for July 29, 2026–</em><br/><em>–Company&apos;s Biologics License Application on track with PDUFA target action date of August 22, 2026–</em></p> <p align="justify">SAN DIEGO, June 26, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=AZcayUcDGZHovCSDoZdE7qPvZOqELzOSExPNopIqX1qKQQKSEWJRQ4LLvXP6FsP1omF3c_iOv4TkY_Iif9If9xqEfRhfp7sL19uZ2dNdLmdJAow914iFJTObmSM2ROKqXwgSbkmsZptlnShlYy8KWryZWI7hUzHPR4g5hj_x1vTdQLCyyczizUgf09B5kLmANdi8dutE9USComoAVelaQlLdJ304Gznwpab0wDkuj27J1BPmTshgs5AojjZEnOzoyDZbT8JzY_YiQgTlBqYO5oDfUoQzChMFa5M20N-AzGfZxXo2Uq28iMS8cw0lat82RZ0qjD72Px58vdVEm_qAmrB9XbiaK4V6miEUQZ78QvhiVQP4zW-CZxm4n8MsX7KGYV5LWOaQWan0BP1RmhAl_9XTBY94HN34cpcV2YVrIiVG3KnVsHPifyjBrwCLjUKE" rel="nofollow" target="_blank">Capricor Therapeutics</a> (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today announced that the Cellular, Tissue, and Gene Therapies Advisory Committee (CTGTAC) of the U.S. Food and Drug Administration (FDA) is planning to convene an advisory committee meeting to discuss the Company&apos;s Biologics License Application (BLA) seeking approval of Deramiocel, an investigational cell therapy for http://www.streetinsider.com/Press+Releases/Capricor+Therapeutics+Announces+FDA+Advisory+Committee+Meeting+to+Review+BLA+for+Deramiocel+for+the+Treatment+of+Duchenne+Muscular+Dystrophy/26695910.html Fri, 26 Jun 2026 10:02:00 -0400 A.06822034 A.25015717 A.31066700 CAPR O.03796190 O.09788428 O.20026344 O.22422661